Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Walgreens Boots Alliance (NASDAQ:WBA) moved higher by 3% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 10.95% year over year to $1.22, which beat the estimate of $1.03.

Walgreens Boots Alliance: Q1 Earnings Insights

Drugstore chain Walgreens Boots Alliance Inc posted a loss on Thursday compared with profit a year earlier, due to a $1.5 billion charge from the its equity earnings in AmerisourceBergen.

Walgreens posts loss on $1.5 billion charge

DEERFIELD, Ill.--(BUSINESS WIRE)-- #earnings--Walgreens Boots Alliance announces financial results for the first quarter of fiscal 2021; accelerates healthcare and omnichannel investments.

Walgreens Boots Alliance Fiscal 2021 First Quarter Results Exceed Expectations

Walgreens Boots Alliance plans to use billions of dollars in proceeds from the sale of its healthcare distribution business on developing its pharmacies for the future.

Walgreens Pessina: We'll Spend Distributor Sale Proceeds On ‘Pharmacy Of The Future'

AmerisourceBergen

Walgreens Boots Alliance Inc (NASDAQ: WBA) disclosed on Wednesday that it had signed an agreement with healthcare products distributor AmerisourceBergen Corp (NYSE: ABC) to sell a majority stake in its Alliance Healthcare business. The deal is valued at $6.5 billion and is expected to close by the end of the fiscal year 2021.

Walgreens Sells Pharmacy Wholesale Unit To AmerisourceBergen For $6.5B

Walgreens Boots Alliance (WBA) has turbo-charged its investment into VillageMD to facilitate the opening of between 600 and 700 new Village Medical at Walgreens primacy care clinics in the next four years, according to a press release. The companies intend to build "hundreds more" in the coming years, too, the release noted.

Walgreens Boots Alliance Accelerates Rollout Of Primary Care Clinics

DEERFIELD, Ill. & CHICAGO--(BUSINESS WIRE)--Walgreens Boots Alliance (WBA) and VillageMD today announced that WBA has accelerated its investment in VillageMD.

Walgreens Boots Alliance Accelerates VillageMD Investment and Large-Scale Rollout of Primary Care Clinics

In an announcement on Wednesday, Walgreens Boots Alliance Inc (NASDAQ: WBA) said it will sell its distribution business to AmerisourceBergen Corp (NYSE: ABC) for £4.78 billion. Walgreens shares were seen more than 2% up in premarket trading on Wednesday and jumped another 2.5% in the next few hours.

Walgreens to sell its distribution unit to AmerisourceBergen for £4.78 billion

The shares of Walgreens Boots Alliance Inc (NASDAQ: WBA) are up 2.5% to trade at $42.18 this morning, after it was reported that the company is selling its Alliance Healthcare businesses to AmerisourceBergen (ABC).

Blue Chip Runs Higher on Buyout Buzz

The large drug wholesaler AmerisourceBergen will acquire the majority of Walgreens Boots Alliance's “Alliance Healthcare business” for $6.5 billion, the companies announced Wednesday.

Walgreens To Sell Wholesale Drug Operation To AmerisourceBergen For $6.5 Billion

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens expects to complete the administration of COVID-19 vaccine first doses in skilled nursing facilities by Monday, Jan. 25. The company is also rapidly expanding access to vaccinations among assisted living facilities and additional vulnerable populations outlined by states and local jurisdictions as part of expanded distribution plans. “Since receiving our first allotments of vaccines in late December, Walgreens has remained on track in vaccinating our

Walgreens Expects to Complete Administration of COVID-19 Vaccine First Doses in Skilled Nursing Facilities by January 25

Walgreens Boots Alliance (NASDAQ:WBA) announces its next round of earnings this Thursday, January 07. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings announcement.

Earnings Outlook for Walgreens Boots Alliance

AmerisourceBergen also raised its guidance, sending shares up more than 6% in early Wednesday trade

Walgreens sells majority of Alliance Healthcare pharmacy business to AmerisourceBergen in $6.5 billion deal

Drug distributor AmerisourceBergen Corp said on Wednesday it would buy Walgreens Boots Alliance's distribution business, Alliance Healthcare, for $6.5 billion.

AmerisourceBergen to buy Walgreens' distribution business in $6.5 billion deal

VALLEY FORGE, Pa. & DEERFIELD, Ill.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) and Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced strategic agreements under which AmerisourceBergen will acquire the majority of Walgreens Boots Alliance's Alliance Healthcare businesses for approximately $6.5 billion, comprised of $6.275 billion in cash and 2 million shares of AmerisourceBergen common stock. AmerisourceBergen's acquisition of Alliance Healthcare will provide even str

AmerisourceBergen and Walgreens Boots Alliance Announce Strategic Transaction

Amgen

Cisco Systems

Chevron

Dow Inc

Coca-Cola

Merck

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

The Dogs of the Dow were flea-bitten last year, but this simple dividend-investing strategy will try to return to greatness in 2021.

Dogs of the Dow 2021: 10 Dividend Stocks to Watch

Walgreens Boots' (WBA) retail pharmacy international sales are likely to remain dull in Q1 on difficult market scenario in the United Kingdom.

Will Walgreens Boots' (WBA) Retail Arm Be Dull in Q1 Earnings?

Walgreens Boots Alliance is scheduled to report its fiscal Q1 2021 results on Thursday, January 7. We expect Walgreens to likely beat the revenue and earnings expectations, driven by higher prescription volume.

Earnings Beat In The Cards For Walgreens Stock?

Boeing

Salesforce

Pfizer

Exxon Mobil

Here are the newest stocks to join the portfolio for those using this easy-to-follow strategy.

Meet the 2021 Dogs of the Dow

Walgreens Boots Alliance is suffering from declining margins and the additional competition by Amazon entering the market is also not great. But the company still has an economic moat around its business and seems to be following the steps of CVS Health.

Walgreens Boots Alliance: Undervalued Dividend Aristocrat

Walgreens has had a tumultuous year. However, it's showing signs of a recovery, which should continue into FY 2021. The wholesale business shows promising growth. Plus, WBA's China footprint is growing rapidly, and VillageMD is on track.

Walgreens Should Be High On Your Watchlist, Here's Why

Visa

Look for these brand-name businesses to be top-performers in the world's most iconic stock index.

3 Dow Stocks That Are Screaming Buys in 2021

Intel

Kroger

Occidental Petroleum

AT&T

Molson Coors Brewing

Vornado Realty Trust

These eight stocks were among the worst value investments of 2020. However, the new year could bring new opportunities.

Here's Why 2020's 8 Worst Value Investments Could Now Merit Another Look

Costco

Constellation Brands

Conagra Brands

Lamb Weston Hlds

Micron Technology

Conagra, Constellation, Lamb Weston, Micron Technology, and Walgreens Boots Alliance report this week. Plus, December jobs data, Fed minutes, and Georgia special Senate elections.

Costco, Walgreens Boots Alliance, Constellation Brands, and Other Stocks to Watch This Week

SPDR Dow Jones Industrial Average ETF

In the 10 days since we posted our preliminary list of 2021's Dogs of the Dow, more than 23,000 Americans have died from causes related to the COVID-19 pandemic.

News for Walgreens Stock (WBA)